Weight Management News and Research

RSS

Semaglutide extended lifespan in older female mice, but that was not the only finding

Late-life semaglutide treatment slowed age-related physiological decline, attenuated multiple molecular hallmarks of aging, and extended median lifespan from 742 to 834 days in aged female mice. The drug reproduced many effects of calorie restriction while providing additional benefits in exploratory behavior, spatial memory, and glucose control, suggesting that some effects extend beyond reduced calorie intake alone.

3 Sep 2026

Smartwatches may overestimate calories burned during exercise

Smartwatches can significantly overestimate how many calories people burn during exercise, and their calorie estimates become less accurate as body fat increases, according to a new Florida International University study.

1 Sep 2026

Study identifies three distinct BMI trajectories among people with type 2 diabetes

A recent study by the University of Eastern Finland identified three distinct body mass index (BMI) trajectories among people with type 2 diabetes.

1 Sep 2026

Semaglutide did more than cut weight in this analysis of 6,239 adults

A systematic review and meta-analysis of nine randomized controlled trials involving 6,239 adults with overweight or obesity without diabetes found that subcutaneous semaglutide produced substantially greater reductions in body weight, waist circumference, and C-reactive protein than placebo. The higher dose of 7.2 mg semaglutide showed potential for greater weight loss, although the evidence is largely based on a single trial and requires confirmation.

31 Aug 2026

GLP-1 drugs may reshape obesity care, but clinicians still have questions

Interviews with 11 healthcare professionals in a UK specialist weight management service found generally positive attitudes toward injectable GLP-1 drugs, alongside limited formal training and uncertainty about how the medications should be integrated with behavioral care. Participants anticipated potential benefits for confidence and weight management but also raised concerns about treatment discontinuation, behavioral engagement, and evolving professional responsibilities.

26 Aug 2026

Consistent meal logging drives major weight loss in app users

The people who log their meals most days of the week lose the most weight. This is the central finding of a peer-reviewed study of 5132 MyNetDiary users, published on August 13, 2026, in the Journal of Medical Internet Research.

25 Aug 2026

A two-year diet trial challenges the idea that weight loss is the only result that matters

In the two-year DELISH randomized trial, adults with obesity achieved modest, sustained weight loss with either an adapted Mediterranean-style program or a commercial weight loss program. The Mediterranean-style intervention produced greater improvements in self-reported diet quality, while 24-month weight loss did not materially differ between groups.

24 Aug 2026

Weight-loss drug users turn to social media over doctors for advice, Coventry University study finds

Researchers from the UK and Canada found that users of GLP-1 medications - weight-loss drugs such as Ozempic, Wegovy and Mounjaro that help regulate appetite and blood sugar levels - often rely on social media, online forums, friends and family for information about the drugs.

19 Aug 2026

Habitual pork consumption supports clinically meaningful weight loss, study finds

According to a peer-reviewed study published May 29, 2026 in Nutrition & Diabetes, adults with overweight or obesity (mean BMI: 33.6 kg/m²; mean age: 47.7 years) who reported continuing to eat pork while participating in a 6-month digital weight management program lost a clinically significant 5.3% of starting body weight and improved their overall diet quality scores by 4.3 points.

18 Aug 2026

What 720,000 adults reveal about artificial sweeteners and diabetes risk

A meta-analysis of six prospective cohort studies involving 721,003 adults found that higher artificial sweetener intake was associated with a 31% greater risk of developing type 2 diabetes. The evidence was rated low certainty because of substantial heterogeneity, observational study designs, and potential residual confounding, meaning the findings do not establish causation.

16 Aug 2026

What happens to body fat when people follow the Eatwell Guide?

Higher adherence to the UK Eatwell Guide was associated with lower BMI, waist circumference, total body fat, and trunk fat in more than 156,000 UK Biobank participants. The associations persisted prospectively across demographic, physical activity, and genetic-risk groups, supporting the role of diet quality in weight management.

16 Aug 2026

Childhood overweight linked to lower childbirth rates later in reproductive life

Women with childhood overweight or obesity trajectories had lower hazards of childbirth from their mid-20s onward, with the strongest associations emerging after age 30. Childhood BMI trajectories were generally not associated with diagnosed infertility, suggesting that biological infertility alone may not explain the reduced childbirth rates.

11 Aug 2026

Low-fat vegan diet helps people lose weight without cutting back on food

A low-fat vegan diet lowers the energy density of the foods people eat by roughly 30%, allowing them to eat satisfying amounts of food while taking in fewer calories and losing weight-without deliberately restricting calories-according to new research published in JAMA Network Open.

7 Aug 2026

Food may taste different on GLP-1 drugs, but taste may not be the reason

The review suggests that patient-reported “taste changes” during GLP-1RA treatment may reflect reduced food enjoyment and motivation rather than consistent impairment of basic taste. The authors propose a sensory-liking-wanting framework while emphasizing that current human evidence remains heterogeneous and largely indirect.

4 Aug 2026

Ten-million-person study links semaglutide to lower COVID-19 mortality

Researchers analyzing claims from more than 10.1 million commercial insurance and Medicare Advantage enrollees found that semaglutide use was associated with a 49% lower adjusted hazard of COVID-19-related death. The observational findings corroborate earlier SELECT trial results but do not establish causation, making further prospective research essential.

30 Jul 2026

Lifestyle habits may explain difference in endometriosis symptoms

Investigating lifestyle factors, this study highlights their role in quality of life for women with endometriosis, advocating for personalized care strategies.

28 Jul 2026

YouTube’s health content rewards attention-grabbing videos over reliable medical information

Researchers analyzed 3,958 Korean-language medical YouTube videos and found that clickbait-heavy content attracted more views, likes, and comments. Higher-quality videos from medical professionals and public institutions often received less attention, highlighting a visibility gap in online health information.

27 Jul 2026

Experts review evidence behind updated protein intake recommendations

A new Perspective published today in The Journal of Nutrition, a peer-reviewed journal of the American Society for Nutrition (ASN), reviews the evidence supporting protein recommendations in the 2025-2030 Dietary Guidelines for Americans and identifies areas where additional research could strengthen future dietary guidance.

24 Jul 2026

Semaglutide vs. liraglutide: Head-to-head study reveals a diabetes risk difference

Researchers compared semaglutide with liraglutide in 57,456 insured adults without recorded diabetes or cardiovascular disease who initiated formulations indicated for chronic weight management. Semaglutide users had a lower risk of incident diabetes, particularly beyond six months of follow-up, but limited cardiovascular events prevented a precise comparison of cardiovascular risk.

20 Jul 2026

Semaglutide fuels rapid growth in US GLP-1RA use as payments rise

Nationally representative US data show GLP-1RA use rose 230% among adults with diabetes and 643% among those without reported diabetes between 2017 and 2022, largely driven by semaglutide. Mean annual out-of-pocket payments decreased, but mean total annual payments per user increased, raising concerns about long-term affordability.